A Phase I/IIa, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT04301011

Study #:
STUDY00145452

Start Date:
Nov 17, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04301011

View Complete Trial Details & Eligibility at ClinicalTrials.gov